M&A Deal Summary

Gilead Sciences Acquires Arresto Biosciences

On December 20, 2010, Gilead Sciences acquired life science company Arresto Biosciences for 225M USD

Acquisition Highlights
  • This is Gilead Sciences’ 8th transaction in the Life Science sector.
  • This is Gilead Sciences’ 17th largest (disclosed) transaction.
  • This is Gilead Sciences’ 7th transaction in the United States.
  • This is Gilead Sciences’ 2nd transaction in California.

M&A Deal Summary
Date 2010-12-20
Target Arresto Biosciences
Sector Life Science
Buyer(s) Gilead Sciences
Deal Type Add-on Acquisition
Deal Value 225M USD

Target

Arresto Biosciences

Palo Alto, California, United States
Arresto Biosciences is a biotechnology company that develops medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis of the extracellular matrix. In addition to AB0024, the company has preclinical candidates targeting proteins associated with various inflammatory diseases. The company is headquartered in Palo Alto, California.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Gilead Sciences

Foster City, California, United States
Category Company
Founded 1987
Sector Life Science
Employees18,000
Revenue 27.1B USD (2023)
DESCRIPTION
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.

DEAL STATS #
Overall 9 of 24
Sector (Life Science) 8 of 23
Type (Add-on Acquisition) 7 of 20
State (California) 2 of 8
Country (United States) 7 of 17
Year (2010) 2 of 2
Size (of disclosed) 17 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-06-25 CGI Pharmaceuticals

Branford, Connecticut, United States

CGI Pharmaceuticals, Inc. is a private, development-stage pharmaceutical company that has leveraged its small molecule chemistry and kinase biology expertise to discover and develop an innovative pipeline of small molecule therapeutics for multiple oncology and immunology-based indications.

Buy $120M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-22 Calistoga Pharmaceuticals

Seattle, Washington, United States

Calistoga Pharmaceuticals is a drug discovery company focused on the development of products for the treatment of cancer and inflammatory diseases. The Company?s initial focus is to leverage a strong proprietary position around the composition and use of drugs against a unique PI3 kinase isoform, p110delta. Calistoga is a privately held organization headquartered in Seattle.

Buy $375M
Mergr

Product

Company

Legal